Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

Sanofi India Ltd - 500674 - Corporate Action-Board approves Dividend

 1. Recommended a final dividend of Rs. 194/- per equity share of the face value of Rs.10/- each and a second special dividend of Rs. 183/- per equity share of the face value of Rs.10/- each for the financial year ended 31st December 2022, subject to approval by the Shareholders at the 67th Annual General Meeting. The Company had earlier paid one-time special interim dividend of Rs. 193/- per equity share on 22nd August 2022. 2. The total dividend for the financial year 2022, including the proposed final dividend, one-time special interim dividend and second special dividend, amounts to Rs. 570/- per equity share of the face value of Rs.10/- each. The Dividend, if approved by the Shareholders will be paid on or after 22nd May 2023;
23-02-2023
Bigul

Sanofi India Ltd - 500674 - Results-Financial Results For The Quarter And Year Ended 31St December 2022

 We refer to our letter dated 7th February 2023 informing you of our Board Meeting that was scheduled today. In this regard, we would like to inform you that the Board of Directors at its meeting held today i.e., Thursday, 23rd February 2023, inter-alia considered and: 1. Approved the financial results of the Company for the quarter and year ended 31st December 2022; Accordingly, we enclose a copy of the auditor's report and audited financial results of the Company for the quarter and year ended 31st December 2022 along with statement of assets and liabilities as on that date and statement of cashflows for the year ended 31st December 2022 as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for your information.
23-02-2023
Bigul

Sanofi India Ltd - 500674 - Board Meeting Outcome for Board Meeting Outcome For Audited Financial Results For The Quarter And Year Ended 31St December 2022

 We refer to our letter dated 7th February 2023 informing you of our Board Meeting that was scheduled today. In this regard, we would like to inform you that the Board of Directors at its meeting held today i.e., Thursday, 23rd February 2023, inter-alia considered and approved matters as per attached documents.
23-02-2023
Bigul

Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has approved issue of duplicate share certificates requests in lieu of the original share certificates reported lost/misplaced.
18-02-2023
Bigul

Sanofi India Ltd - 500674 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Company will hold an investor / analysts call on 24th February 2023 at 2:00 p.m. Kindly refer to the attached file for details.
16-02-2023
Bigul

Sanofi India Ltd - 500674 - Board Meeting Intimation for Approval Of Audited Accounts For The Quarter And Year Ended 31St December 2022 And For Recommendation Of Dividend, If Any, For The Financial Year Ended 31St December 2022.

 Sanofi India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/02/2023 ,inter alia, to consider and approve 1) the audited accounts for the quarter and year ended 31st December 2022 and 2) recommend dividend, if any, for the financial year ended 31st December 2022.
07-02-2023
Bigul

Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate(s)
06-02-2023

Sanofi to let go of staff at vaccine plants in India as part of review

 The drugmaker is offering voluntary retirement scheme (VRS) to all its employees at two sites near Hyderabad
30-01-2023
Bigul

Sanofi India Ltd - 500674 - Certificate Under Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Year Ended 31St December 2022

 Pursuant to Regulation 40 (9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith Certificate of M/s. Makarand M. Joshi & Co., Company Secretaries for the year ended 31st December 2022
27-01-2023
Bigul

Sanofi India Ltd - 500674 - Compliance Certificate For The Year Ended 31St December,2022

 As required under Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby confirm that activities in relation to both physical and electronic share transfer facility were maintained by the Company's Registrar and Share Transfer Agent, viz., Link Intime India Private Limited, which is registered as Registrar & Share Transfer Agent in Category - I with SEBI vide Registration Number : INR000004058 for the year ended 31st December 2022.
20-01-2023
Next Page
Close

Let's Open Free Demat Account